VivaVision Biotech
Latest round
- Series D
Last raised
- May 2023
Total raised
- $80M
Investors
- 19
About VivaVision Biotech
Based in Shanghai, China, and founded in 2016, VivaVision Biotech, Inc. is a biopharmaceutical company that focused on the R&D of new drugs for ophthalmic diseases and dermal inflammatory diseases. The company also established a branch office in Jiaxing. In July 2025, VivaVision Biotech, Inc. Since 2020, the company has had clinical testing in the USA and China. The CEO of the company Dr. Shen Wang, was the founder and CEO of Kanion USA. The company developed new drugs to treat ophthalmic diseases and dermal inflammatory diseases. The pipeline VVN001 can be used for treating dry eye diseases, The pipeline VVN460 can be used for treating plaque psoriasis. The pipeline VVN539 can be used for treating glaucoma. The pipeline vvn001 is in the clinical stage, and other ocular surfaces and fundus treatment products are in different stages of development.
Who invested in VivaVision Biotech
19 investors across 6 rounds
See all investors in VivaVision Biotech
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about VivaVision Biotech
Who invested in VivaVision Biotech?
VivaVision Biotech has 19 investors on record across 6 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has VivaVision Biotech raised?
VivaVision Biotech has raised 6 venture rounds. Sign up free to see how much each round raised and the total.
When did VivaVision Biotech last raise money?
VivaVision Biotech's most recent round on record is a Series D, in May 2023.
What does VivaVision Biotech do?
Based in Shanghai, China, and founded in 2016, VivaVision Biotech, Inc.
Where is VivaVision Biotech headquartered?
VivaVision Biotech is headquartered in Wenzhou, China.
Which VCs invest in companies like VivaVision Biotech?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back healthcare specialists companies at VivaVision Biotech's stage. Their profiles are linked below.
VCs backing healthcare specialists startups at Series D
Raising like VivaVision Biotech? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.